
Intra-Cellular reports positive results in depression study
Intra-Cellular Therapies announced positive results from a Phase 3 clinical trial for its antipsychotic medicine Caplyta in treating major depressive disorder. The study showed a significant reduction in depressive symptoms compared to a placebo on the MADRS scale. The drug also demonstrated benefits on a patient-reported measure of depression severity. Common side effects included dry…